PL371278A1 - Zmodyfikowany czynnik VIII - Google Patents

Zmodyfikowany czynnik VIII

Info

Publication number
PL371278A1
PL371278A1 PL03371278A PL37127803A PL371278A1 PL 371278 A1 PL371278 A1 PL 371278A1 PL 03371278 A PL03371278 A PL 03371278A PL 37127803 A PL37127803 A PL 37127803A PL 371278 A1 PL371278 A1 PL 371278A1
Authority
PL
Poland
Prior art keywords
factor viii
fviii
modified
modified factor
immunogenic
Prior art date
Application number
PL03371278A
Other languages
English (en)
Inventor
Tim Jones
Matthew Baker
Francis J. Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL371278A1 publication Critical patent/PL371278A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL03371278A 2002-04-18 2003-04-17 Zmodyfikowany czynnik VIII PL371278A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02008712 2002-04-18
EP03006554 2003-03-24

Publications (1)

Publication Number Publication Date
PL371278A1 true PL371278A1 (pl) 2005-06-13

Family

ID=29252205

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03371278A PL371278A1 (pl) 2002-04-18 2003-04-17 Zmodyfikowany czynnik VIII

Country Status (15)

Country Link
US (1) US20050256304A1 (pl)
EP (1) EP1495052B9 (pl)
JP (1) JP2005538694A (pl)
KR (1) KR20040103970A (pl)
CN (1) CN1646564A (pl)
AT (1) ATE412671T1 (pl)
AU (1) AU2003232482A1 (pl)
BR (1) BR0308860A (pl)
CA (1) CA2482926A1 (pl)
DE (1) DE60324406D1 (pl)
ES (1) ES2319758T3 (pl)
MX (1) MXPA04010061A (pl)
PL (1) PL371278A1 (pl)
RU (1) RU2004133761A (pl)
WO (1) WO2003087161A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2780763A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii b cell epitope variants having reduced immunogenicity
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
PL3260132T3 (pl) * 2010-10-27 2022-08-08 Takeda Pharmaceutical Company Limited Peptydy fviii do wywoływania tolerancji immunologicznej oraz immunodiagnostyki
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
WO2014152530A1 (en) * 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
JP7274472B2 (ja) * 2017-10-05 2023-05-16 エピバックス、インコーポレイテッド 制御性ｔ細胞エピトープ
CN112119158A (zh) * 2018-04-12 2020-12-22 生物测试股份公司 去免疫化的因子viii分子以及包含其的药物组合物
US12091675B2 (en) * 2018-07-16 2024-09-17 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US20020068303A1 (en) * 1994-07-14 2002-06-06 Ruth Laub Antigenic polypeptide sequences of factor VIII, and fragments and/or epitopes of these sequences
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1997003195A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools

Also Published As

Publication number Publication date
JP2005538694A (ja) 2005-12-22
KR20040103970A (ko) 2004-12-09
MXPA04010061A (es) 2004-12-13
BR0308860A (pt) 2005-01-04
EP1495052B1 (en) 2008-10-29
CN1646564A (zh) 2005-07-27
CA2482926A1 (en) 2003-10-23
EP1495052B9 (en) 2009-12-16
US20050256304A1 (en) 2005-11-17
ES2319758T3 (es) 2009-05-12
EP1495052A1 (en) 2005-01-12
ATE412671T1 (de) 2008-11-15
AU2003232482A1 (en) 2003-10-27
DE60324406D1 (de) 2008-12-11
RU2004133761A (ru) 2005-07-10
WO2003087161A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
DE60324406D1 (de) Modifizierter faktor viii
MXPA04001982A (es) Factor ix modificado.
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
MXPA03008715A (es) Reduccion de la inmunogenicidad de proteinas de fusion.
IL185763A0 (en) Peptides that lower blood glucose levels
EP1724282A3 (en) Method for the production of non-immunogenic proteins
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
WO2005049073A3 (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
DE60322225D1 (en) T-zellen-epitope in erythropoietin
MXPA04001976A (es) Hormona de crecimiento humano modificada.
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
WO2002070665A8 (en) Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
MXPA04004970A (es) Epitopos de linfocitos t en carboxipeptidasa g2.
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
WO2003006047A3 (en) Methods for reducing immunogenicity of polypeptides
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
EP1372691A4 (en) MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)